Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
Logo Image
|Articles|August 2, 1995

Myoview receives approvable letter

Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based

Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based imaging productand will compete with Du Pont Merck's Cardiolite agent. Medi-Physicswill emphasize the fast clearance of Myoview as well as the product'sease of use compared to thallium agents. Final FDA approval isexpected within a few months, according to the company.

Related to this article

View more
Emerging Research Insights and New Advances in Neuroradiology
Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Read more
Current Perspectives on Integrating AI into Radiology
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Read more